CBS 2019
CBSMD教育中心
中 文

双重抗血小板治疗持续时间

Abstract

Recommended Article

Does Risk of Premature Discontinuation of Dual-Antiplatelet Therapy Following PCI Attenuate With Increasing Age? Impact of bleeding during dual antiplatelet therapy in patients with coronary artery disease Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI A prospective, randomized, open-label trial of 6-month versus 12-month dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction: Rationale and design of the Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Patients With ST-Segment Elevation Myocardial Infarction Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial

JOURNAL:CBS2017 Article Link

CBS Insight Serie Dialogue with World Renownd Cardiologists

CBS2017


CBS2017 has set up a special interview session CBS Insight interviews world class cardiologists to analyze the hot spots and difficulties in the current clinical research from the perspective of historical review and outlook in the future. Please click here to visit the CBS2017 official website interview page to watch CBS Insight interview videos.